Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ingenol mebutate - LEO Pharma

Drug Profile

Ingenol mebutate - LEO Pharma

Alternative Names: 3-Ingenyl angelate; I3A; Ingenol-3-angelate; PEP-005; PEP005-015; Picato

Latest Information Update: 29 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer LEO Pharma; Peplin
  • Class Antineoplastics; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • No development reported Basal cell cancer; Bladder cancer; Leukaemia; Squamous cell cancer; Warts

Most Recent Events

  • 11 Feb 2020 Discontinued - Registered for Actinic keratosis in European Union (Topical)
  • 11 Feb 2020 Withdrawn for Actinic keratosis in Iceland (Topical)
  • 11 Feb 2020 The European Commission withdrew the marketing authorisation of ingenol mebutate (Picato®) gel for the treatment of actinic keratosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top